Latest Strong buzz on streets –

Dilip Sanghvi of Sun Pharma has acquired additional 2% stake in the company in the past 15 days thereby totaling close to 5%.

Sun Pharma and Ranbaxy are going to announce strategic tie up soon .

Ranbaxy will use the FDA approved manufacturing facilities of Sun Pharma to supply drugs to US. In turn Ranbaxy will delist the shares at Rs. 750 per share within a month.

Sources at daichi say that after the recent meeting of commerce ministry, the US FDA officials have assured that the Tonsa plant of Ranbaxy will get approval soon.